Vertex Pharmaceuticals Inc (VRTX : NASDAQ)
Common Stock
$513.26
USD
+0.00 (%)
Last updated: 2026-09-17
Get VRTX alerts:
VRTX
Vertex Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-0.27%
1 Week
-1.51%
1 Month
-0.44%
YTD
+11.82%
Key Statistics
Market Cap
$130.09B
52W High
$560.25
52W Low
$374.17
P/E Ratio
29.95
50 Day MA
$510.00
200 Day MA
$469.33
Beta
0.32
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $518.35 | $519.07 | $510.19 | $516.34 | $516.34 | 887,319 |
| 9/16/2026 | $513.80 | $517.95 | $511.35 | $513.26 | $513.26 | 637,442 |
| 9/15/2026 | $519.94 | $519.94 | $511.00 | $514.63 | $514.63 | 824,890 |
| 9/14/2026 | $522.17 | $525.29 | $514.65 | $519.51 | $519.51 | 837,109 |
| 9/11/2026 | $522.10 | $522.10 | $511.81 | $515.44 | $515.44 | 875,635 |
| 9/10/2026 | $519.13 | $522.60 | $514.32 | $514.56 | $514.56 | 815,000 |
| 9/9/2026 | $524.00 | $528.17 | $520.08 | $521.12 | $521.12 | 958,300 |
| 9/8/2026 | $529.64 | $535.00 | $520.20 | $528.90 | $528.90 | 1,121,100 |
| 9/4/2026 | $549.50 | $556.99 | $544.48 | $546.12 | $546.12 | 803,300 |
| 9/3/2026 | $559.00 | $560.25 | $551.61 | $557.96 | $557.96 | 800,700 |
Analyst Price Targets
Based on 34 analysts covering VRTX · as of Sep 17, 2026
Wall Street analysts forecast VRTX stock price to rise 10.9% over the next 12 months.
Consensus
Buy3.85 / 5.00
Avg. Target
US$569.19
+10.9% Upside
Current Price
US$513.26
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
30.5%
Annualized
90-Day Vol
30.0%
Annualized
Trend (90d)
+40.9%
Annualized drift
90d Mean
US$597.57
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$542.11 | US$488.03 – US$602.18 |
| 60 trading days | US$569.16 | US$490.56 – US$660.36 |
| 90 trading days | US$597.57 | US$498.12 – US$716.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Financials
- Revenue (TTM)
- $12.59B
- EBITDA
- $5.10B
- Profit Margin
- 35.00%
- ROE (TTM)
- 23.54%
- EPS (Diluted)
- 17.14
- Book Value
- 79.92
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VRTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
VRTX.US news timeline
5 articles covering VRTX.US, most recent first
Latest